Product Information
Registration Status: ActiveSIN15097P
DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION is approved to be sold in Singapore with effective from 2016-10-11. It is marketed by SANOFI-AVENTIS SINGAPORE PTE LTD, with the registration number of SIN15097P.
This product contains CYD Dengue Virus Serotype 1 Each strain: 4.5 - 6.0 log10 CCID50/dose,CYD Dengue Virus Serotype 2 ,CYD Dengue Virus Serotype 3 , and CYD Dengue Virus Serotype 4 in the form of SUBCUTANEOUS INJECTION, POWDER, FOR SUSPENSION. It is approved for SUBCUTANEOUS use.
This product is manufactured by Sanofi Pasteur (VDR) in FRANCE.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.